Investor events

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events: H.C. Wainwright Global Life Sciences Conference – Monaco...

Proposals to appoint Supervisory board members and renew members’ mandates at the Annual General Meeting. Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), announces that it will host an event for analysts and investors in London to discuss the Company’s corporate strategy and ongoing...

Update on strategy and pipeline Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events during the second quarter of 2016: Gilbert Dupont...

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on June 2, 2016, at 10:00 am in its headquarters, 117 avenue de Luminy...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today...